Key facts
- This page summarizes Terrie Curran's Form 4 filing for Phathom Pharmaceuticals, Inc. (PHAT).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 23 Jan 2025, 16:19.
Terrie Curran - 21 Jan 2025 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)
- Reporting relationship
- President and Chief Executive, Director
- Issuer ticker
- PHAT
- Reported as of
- 21 Jan 2025
- Net transaction value
- -$125,884
- SEC form
- 4
- Accepted by SEC
- 23 Jan 2025, 16:19:11 UTC
- Prior SEC filing
- 13 Nov 2024
- Next SEC filing
- 03 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Molly Henderson, Attorney-in-Fact for Terrie Curran
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Terrie Curran filed Form 4 for Phathom Pharmaceuticals, Inc. (PHAT) on 23 Jan 2025.
Change
- Previous filing in this sequence was filed on 13 Nov 2024.
- Current net transaction value: -$125,884.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PHAT
transaction
Common Stock
Sale
- Transaction value
- $125,884
- Shares
- -19,109
- Change %
- -5%
- Price
- $6.59
- Shares after
- 360,465
- Date
- 21 Jan 2025
- Ownership
- Direct
- Footnotes
- F1, F2, F3
PHAT
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,840
- Date
- 21 Jan 2025
- Ownership
- By 401(k)
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.5855 to $6.6503. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
Includes 1,840 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2025.